Home » Market News » DirectorsTalk Highlights » Parkinson’s warning as cases set to treble in global pandemic
Immupharma Plc

Parkinson’s warning as cases set to treble in global pandemic

By 2040 there could be more than 17 million sufferers across the world, compared with the six million now.

Scientists say the rise is being fuelled by industrialisation, with pesticides, solvents and heavy metals linked to the condition. Other factors include ageing populations and fewer people smoking as, paradoxically, smokers are 40 per cent less likely to be struck down.

Study lead author Professor Ray Dorsey, a neurologist at Rochester University in New York, said: “Parkinson’s exacts an enormous human toll on those with the disease and those around them.”

 

ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.